Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSMB-07811 is a liver-targeted prodrug form of the thyroid hormone receptor β (TRβ) agonist MB-07344.1 It is stable in extrahepatic tissues and converted to MB-07344 in the liver. MB-07811 binds to TRα1 and TRβ1 with Ki values of 12.5 and 14.6 µM, respectively. Oral administration of MB-07811 reduces plasma cholesterol levels (ED50 = 0.48 mg/kg) in a cholesterol-fed rat (CFR) model. It also reduces hepatic steatosis, as well as plasma levels of cholesterol, in Zucker diabetic fatty rats in a model of non-alcoholic fatty liver disease (NAFLD) when administered at a dose of 5 mg/kg per day.2 MB-07811 (10 mg/kg) reverses hepatic steatosis, reducing total hepatic lipids without decreasing body weight, in a mouse model of diet-induced obesity.
WARNING This product is not for human or veterinary use.
1. Synthesis and biological evaluation of a series of liver-
2. Reduction of hepatic steatosis in rats and mice after treatment with a liver-